Macari D, Whitebread S, Cumin F, De Gasparo M, Levens N
Ciba-Geigy Ltd., Basel, Switzerland.
Eur J Pharmacol. 1994 Jun 23;259(1):27-36. doi: 10.1016/0014-2999(94)90153-8.
The purpose of this study was to investigate whether the selective angiotensin AT2 receptor ligands, CGP 42112B (Nic-Tyr-(N alpha-benzoyloxycarbonyl-Arg)Lys-His-Pro-Ile-OH) and PD 123319 ((s)-1-[[4-(dimethylamino)-3-methyl-phenyl]methyl]-5-(diphenylacetyl+ ++)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]-pyridine-6-carboxylic acid) are agonists at angiotensin receptors influencing blood pressure and renal function in the enalaprilat-treated anesthetized rat. The agonist angiotensin II significantly increased blood pressure and renal vascular resistance. Glomerular filtration rate was unchanged by angiotensin II. Effective renal blood flow decreased significantly in response to angiotensin II leading to a significant increase in filtration fraction. Angiotensin II did not induce significant change in urinary potassium excretion or free water formation but significantly increased both urine volume and urinary sodium excretion. At doses up to 3 orders of magnitude greater than angiotensin II, CGP 42112B also significantly increased blood pressure, filtration fraction, glomerular filtration rate, urine volume and urinary sodium excretion, but did not significantly affect effective renal blood flow or renal vascular resistance. The selective angiotensin AT2 receptor ligand PD 123319 had no significant effects on blood pressure nor any measured parameter of renal function. The changes in blood pressure and renal function produced by angiotensin II and CGP 42112B could be completely blocked by the angiotensin AT1 receptor antagonist losartan. The results therefore only support a role for angiotensin AT1 receptors and not angiotensin AT2 receptors in the control of renal function in the rat and demonstrate that at high doses the angiotensin AT2 selective ligand CGP 42112B behaves as an agonist at angiotensin AT1 receptors.
本研究旨在探究选择性血管紧张素AT2受体配体CGP 42112B(烟碱 - 酪氨酸 -(Nα - 苯甲酰氧基羰基 - 精氨酸)赖氨酸 - 组氨酸 - 脯氨酸 - 异亮氨酸 - 羟基)和PD 123319((s)-1 - [[4 -(二甲基氨基)-3 - 甲基 - 苯基]甲基] - 5 -(二苯基乙酰基)-4,5,6,7 - 四氢 - 1H - 咪唑并[4,5 - c] - 吡啶 - 6 - 羧酸)是否作为血管紧张素受体的激动剂影响依那普利拉治疗的麻醉大鼠的血压和肾功能。激动剂血管紧张素II显著升高血压和肾血管阻力。血管紧张素II对肾小球滤过率无影响。有效肾血流量因血管紧张素II而显著降低,导致滤过分数显著增加。血管紧张素II未引起尿钾排泄或自由水生成的显著变化,但显著增加尿量和尿钠排泄。在比血管紧张素II高3个数量级的剂量下,CGP 42112B也显著升高血压、滤过分数、肾小球滤过率、尿量和尿钠排泄,但对有效肾血流量或肾血管阻力无显著影响。选择性血管紧张素AT2受体配体PD 123319对血压和任何测量的肾功能参数均无显著影响。血管紧张素II和CGP 42112B引起的血压和肾功能变化可被血管紧张素AT1受体拮抗剂氯沙坦完全阻断。因此,结果仅支持血管紧张素AT1受体而非AT2受体在大鼠肾功能控制中的作用,并表明高剂量时血管紧张素AT2选择性配体CGP 42112B表现为血管紧张素AT1受体的激动剂。